These data indicate that there is a new mTOR independent progranulin-related pathway in the proliferation of Kasumi-1 cells, and progranulin will be a target of new therapeutic strategy to hematopoietic cancers. Here, GRN is linked to hematopoietic and lymphoid cell neoplasm.